Skip to main content

Advertisement

Log in

Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

A Correction to this article was published on 04 February 2020

This article has been updated

Abstract

Introduction

We investigated whether rheumatoid arthritis (RA)-related autoantibodies were associated with abnormalities on pulmonary function tests (PFTs).

Methods

We studied RA serostatus and PFT abnormalities within a RA registry. RA serostatus was assessed by research assays for cyclic citrullinated peptide (CCP) and rheumatoid factor (RF). Outcomes were abnormalities on clinically indicated PFTs, including restriction, obstruction, and diffusion abnormality. Logistic regression was used to obtain ORs and 95% CIs for the PFT abnormalities by RA serologic phenotypes independent of lifestyle and RA characteristics.

Results

Among 1272 analyzed subjects, mean age was 56.3 years (SD 14.1), 82.2% were female, and 69.5% were seropositive. There were 100 subjects with abnormal PFTs. Compared with seronegativity, seropositivity was associated with increased odds of any PFT abnormality (multivariable OR 2.29, 95% CI 1.30–4.03). When analyzing type of PFT abnormality, seropositivity was also associated with restriction, obstruction, and diffusion abnormalities; multivariable ORs were 2.48 (95% CI 1.26–4.87), 3.12 (95% CI 1.28–7.61), and 2.30 (95% CI 1.09–4.83), respectively. When analyzing by CCP and RF status, the associations were stronger for RF+ than for CCP+ (any PFT abnormality OR 1.99, 95% CI 1.21–3.27 for RF+ vs. RF−; OR 1.67, 95% CI 1.03–2.69 for CCP+ vs. CCP−) with a dose effect of higher RF titer increasing odds for each PFT abnormality (p for trend < 0.05).

Conclusions

Seropositive RA patients had two-fold increased risk for abnormalities on PFTs performed for clinical indications compared with seronegative RA. Patients with seropositive RA, particularly those with high-titer RF positivity, may be more likely to have obstructive and restrictive abnormalities, independent of smoking.

Key points

• Due to the known excess pulmonary morbidity/mortality in RA, we studied the relationship of rheumatoid arthritis (RA)-related autoantibodies with pulmonary function test (PFT) abnormalities using a large RA registry.

• We evaluated whether presence and levels of cyclic citrullinated peptide (CCP) and rheumatoid factor (RF) were associated with restriction, obstruction, and diffusion abnormalities on PFTs among 1272 subjects with RA.

• Seropositivity was associated with two-fold increased risk for any PFT abnormality, independent of confounders including smoking. Higher titers of RF conferred greatest risk for all PFT outcomes: obstruction, restriction, and diffusion abnormality.

• These results provide evidence that patients with RA should be closely monitored for pulmonary involvement, particularly those with high-titer RF seropositivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Change history

  • 04 February 2020

    The publisher regrets that the two sections under the Results omitted inadvertently on the original published version of the above article.

References

  1. Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL (2003) Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 62(8):722–727

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Nannini C, Ryu JH, Matteson EL (2008) Lung disease in rheumatoid arthritis. Curr Opin Rheumatol 20(3):340–346

    Article  PubMed  Google Scholar 

  3. Shaw M, Collins BF, Ho LA, Raghu G (2015) Rheumatoid arthritis-associated lung disease. Eur Respir Rev 24(135):1–16

    Article  PubMed  Google Scholar 

  4. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 62(6):1583–1591

    Article  PubMed  PubMed Central  Google Scholar 

  5. Liao KP, Sparks JA, Hejblum BP, Kuo IH, Cui J, Lahey LJ, Cagan A, Gainer VS, Liu W, Cai TT, Sokolove J, Cai T (2017) Phenome-wide association study of autoantibodies to citrullinated and noncitrullinated epitopes in rheumatoid arthritis. Arthritis Rheumatol 69(4):742–749

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Shadick NA, Fanta CH, Weinblatt ME, O’Donnell W, Coblyn JS (1994) Bronchiectasis. A late feature of severe rheumatoid arthritis. Medicine (Baltimore) 73(3):161–170

    Article  CAS  Google Scholar 

  7. Doyle TJ, Dellaripa PF (2017) Lung manifestations in the rheumatic diseases. Chest. 152(6):1283–1295

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hassan WU, Keaney NP, Holland CD, Kelly CA (1994) Bronchial reactivity and airflow obstruction in rheumatoid arthritis. Ann Rheum Dis 53(8):511–514

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, Dawson J, Sathi N, Ahmad Y, Koduri G, Young A, on behalf of the British Rheumatoid Interstitial Lung (BRILL) Network (2014) Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology (Oxford) 53(9):1676–1682

    Article  CAS  Google Scholar 

  10. Brown KK (2007) Roger S. Mitchell Lecture. Rheumatoid Lung Disease. Proc Am Thorac Soc 4(5):443–448

    Article  PubMed  PubMed Central  Google Scholar 

  11. Pappas DA, Giles JT, Connors G, Lechtzin N, Bathon JM, Danoff SK (2010) Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study. Arthritis Res Ther 12(3):R104

    Article  PubMed  PubMed Central  Google Scholar 

  12. Wilsher M, Voight L, Milne D, Teh M, Good N, Kolbe J, Williams M, Pui K, Merriman T, Sidhu K, Dalbeth N (2012) Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respir Med 106(10):1441–1446

    Article  PubMed  Google Scholar 

  13. Hwang J, Song JU, Ahn JK (2016) Decline of pulmonary function is associated with the presence of rheumatoid factor in Korean health screening subjects without clinically apparent lung disease: a cross-sectional study. Medicine (Baltimore) 95(19):e3668

    Article  Google Scholar 

  14. Robles-Perez A, Luburich P, Rodriguez-Sanchon B, Dorca J, Nolla JM, Molina-Molina M, Narvaez-Garcia J (2016) Preclinical lung disease in early rheumatoid arthritis. Chron Respir Dis 13(1):75–81

    Article  PubMed  PubMed Central  Google Scholar 

  15. Aubart F, Crestani B, Nicaise-Roland P, Tubach F, Bollet C, Dawidowicz K et al (2011) High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol 38(6):979–982

    Article  CAS  PubMed  Google Scholar 

  16. Paschalaki KE, Jacob J, Wells AU (2016) Monitoring of lung involvement in rheumatologic disease. Respiration. 91(2):89–98

    Article  PubMed  Google Scholar 

  17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324

    Article  CAS  PubMed  Google Scholar 

  18. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580–1588

    Article  PubMed  Google Scholar 

  19. Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, Solomon DH, Weinblatt ME, Shadick NA (2011) Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford) 50(1):40–46

    Article  CAS  Google Scholar 

  20. Doyle TJ, Dellaripa PF, Batra K, Frits ML, Iannaccone CK, Hatabu H, Nishino M, Weinblatt ME, Ascherman DP, Washko GR, Hunninghake GM, Choi AMK, Shadick NA, Rosas IO (2014) Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest. 146(1):41–50

    Article  PubMed  Google Scholar 

  21. Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, Golzarri MF, Traslosheros A, Chu SG, Frits ML, Iannaccone CK, Koontz D, Fuhrman C, Weinblatt ME, el-Chemaly SY, Washko GR, Hunninghake GM, Choi AMK, Dellaripa PF, Oddis CV, Shadick NA, Ascherman DP, Rosas IO (2015) Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med 191(12):1403–1412

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Bohler C, Radner H, Smolen JS, Aletaha D (2013) Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. Ann Rheum Dis 72(2):241–244

    Article  CAS  PubMed  Google Scholar 

  23. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A (2017) Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med 195(5):557–582

    Article  CAS  PubMed  Google Scholar 

  24. Johnson JD, Theurer WM (2014) A stepwise approach to the interpretation of pulmonary function tests. Am Fam Physician 89(5):359–366

    PubMed  Google Scholar 

  25. Radner H, Yoshida K, Mjaavatten MD, Aletaha D, Frits M, Lu B, Iannaccone C, Shadick N, Weinblatt M, Hmamouchi I, Dougados M, Smolen JS, Solomon DH (2015) Development of a multimorbidity index: impact on quality of life using a rheumatoid arthritis cohort. Semin Arthritis Rheum 45(2):167–173

    Article  PubMed  Google Scholar 

  26. Quinn T, Bs MF, von Heideken J, Iannaccone C, Shadick NA, Weinblatt M et al (2017) Validity of the nurses’ health study physical activity questionnaire in estimating physical activity in adults with rheumatoid arthritis. BMC Musculoskelet Disord 18(1):234

    Article  PubMed  PubMed Central  Google Scholar 

  27. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48

    Article  CAS  PubMed  Google Scholar 

  28. Pincus T, Swearingen C, Wolfe F (1999) Toward a multidimensional health assessment questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 42(10):2220–2230

    Article  CAS  PubMed  Google Scholar 

  29. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R et al (2005) Interpretative strategies for lung function tests. Eur Respir J 26(5):948–968

    Article  CAS  PubMed  Google Scholar 

  30. Barrera P, Laan RF, van Riel PL, Dekhuijzen PN, Boerbooms AM, van de Putte LB (1994) Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 53(7):434–439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Perez T, Remy-Jardin M, Cortet B (1998) Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 157(5 Pt 1):1658–1665

    Article  CAS  PubMed  Google Scholar 

  32. Youssef AA, Machaly SA, El-Dosoky ME, El-Maghraby NM (2012) Respiratory symptoms in rheumatoid arthritis: relation to pulmonary abnormalities detected by high-resolution CT and pulmonary functional testing. Rheumatol Int 32(7):1985–1995

    Article  PubMed  Google Scholar 

  33. Perry E, Kelly C, Eggleton P, De Soyza A, Hutchinson D (2014) The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury? Rheumatology (Oxford) 53(11):1940–1950

    Article  CAS  Google Scholar 

  34. Zhu J, Zhou Y, Chen X, Li J (2014) A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol 41(7):1282–1289

    Article  PubMed  Google Scholar 

  35. Mori S, Koga Y, Sugimoto M (2012) Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 106(11):1591–1599

    Article  PubMed  Google Scholar 

  36. Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER, Huie TJ, Stevens AD, Gill MB, Rabinovitch AM, Lynch DA, Burns DA, Pineiro IS, Groshong SD, Duarte Achcar RD, Brown KK, Martin RJ, Swigris JJ (2012) Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 106(7):1040–1047

    Article  PubMed  PubMed Central  Google Scholar 

  37. Tuomi T, Heliovaara M, Palosuo T, Aho K (1990) Smoking, lung function, and rheumatoid factors. Ann Rheum Dis 49(10):753–756

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ford JA, Liu X, Marshall AA, Zaccardelli A, Prado MG, Wiyarand C, Lu B, Karlson EW, Schur PH, Deane KD, Sparks JA (2018) Impact of cyclic citrullinated peptide antibody level on progression to rheumatoid arthritis in clinically tested CCP-positive patients without RA. Arthritis Care Res (Hoboken)

  39. Bergstrom U, Jacobsson LT, Nilsson JA, Berglund G, Turesson C (2011) Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. Rheumatology (Oxford) 50(11):2005–2013

    Article  Google Scholar 

  40. Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE, Parker A, Roubenoff R, Izmailova E, Coblyn JS, Weinblatt ME, Shadick NA (2008) Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis 67(3):358–363

    Article  CAS  PubMed  Google Scholar 

  41. Balsa A, Cabezon A, Orozco G, Cobo T, Miranda-Carus E, Lopez-Nevot MA et al (2010) Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor. Arthritis Res Ther. 12(2):R62

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR (2006) The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 54(4):1117–1121

    Article  CAS  PubMed  Google Scholar 

  43. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54(1):38–46

    Article  CAS  PubMed  Google Scholar 

  44. Luukkainen R, Saltyshev M, Pakkasela R, Nordqvist E, Huhtala H, Hakala M (1995) Relationship of rheumatoid factor to lung diffusion capacity in smoking and non-smoking patients with rheumatoid arthritis. Scand J Rheumatol 24(2):119–120

    Article  CAS  PubMed  Google Scholar 

  45. Tseng HJ, Henry TS, Veeraraghavan S, Mittal PK, Little BP (2017) Pulmonary function tests for the radiologist. Radiographics. 37(4):1037–1058

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Elizabeth W. Karlson, MD, MS for her support and guidance. We thank Vivi Feathers for the assistance in data management and statistical analysis. We thank the dedicated RA participants and staff of the Brigham Rheumatoid Arthritis Sequential Study (BRASS) at Brigham and Women’s Hospital for their continued participation in this longitudinal research study.

Funding

This work was supported by the Rheumatology Research Foundation K Supplement Award and the National Institutes of Health (grant numbers K23 AR069688, K23 HL119558, R03 AR075886, L30 AR066953, R01 AR049880, P30 AR070253, and P30 AR072577). The Brigham Rheumatoid Arthritis Sequential Study is funded by grants from Bristol-Myers Squibb, Crescendo Bioscience, and Sanofi/Regeneron. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic health care centers, or the National Institutes of Health.

Author information

Authors and Affiliations

Authors

Contributions

All authors were involved in drafting the article or revising it critically for important intellectual contact, and all authors approved the final version to be published. Huang, He, Shadick, and Sparks were involved in the study conception and design; Huang, Zaccardelli, Marshall, Friedlander, Blaustein, Smith, Cui, Iannaccone, Mahmoud, Weinblatt, Shadick and Sparks in acquisition of data; and Huang, He, Doyle, Zaccardelli, Marshall, Friedlander, Cui, Iannaccone, Mahmoud, Weinblatt, Dellaripa, Shadick and Sparks in data analysis and interpretation. Dr. Huang had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Corresponding authors

Correspondence to Sicong Huang or Jeffrey A. Sparks.

Ethics declarations

The study protocol and informed consent document were reviewed and approved by the Partners HealthCare Institutional Review Board. All subjects provided written informed consent before participating in the BRASS registry.

Conflict of interest

Tracy J. Doyle reports research funding from Bristol-Myers Squibb and involvement in a clinical trial funded by Genentech. Paul F. Dellaripa reports research funding from Bristol-Myers Squibb and involvement in a clinical trial funded by Genentech. Michael E. Weinblatt reports research grants from Amgen, Crescendo Bioscience, Sanofi/Regeneron, and Bristol-Myers Squibb; consultancy to Abbvie, Amgen, Bristol-Myers Squibb, Canfite, Corrona, Crescendo Bioscience, GlaxoSmithKline, Gilead, Lilly, Lycera, Merck, Novartis, Pfizer, Roche, Samsung, Set Point, and Scipher; and stock options in Lycera, Canfite, Scipher, Vorso, and Inmedix. Nancy A. Shadick reports research funding from Bristol-Myers Squibb, Crescendo Biosciences, Sanofi Regeneron, and Mallinckrodt; and consultancy to Bristol-Myers Squibb. Jeffrey A. Sparks reports research funding from Bristol-Myers Squibb and Amgen and consultancy to Optum.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 30 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, S., He, X., Doyle, T.J. et al. Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry. Clin Rheumatol 38, 3401–3412 (2019). https://doi.org/10.1007/s10067-019-04733-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-019-04733-9

Keywords

Navigation